Phase I, open-label study to evaluate the safety and immune activity of PeptiCRAd-1, an oncolytic virus coated with tumor-specific peptides in combination with the immunotherapy drug pembrolizumab in patients with injectable solid tumors in defined indications

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517580-23-00

Acronym

VALO-001

Enrollment

Registered

2024-11-08

Start date

2023-03-07

Completion date

Unknown

Last updated

2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer, Melanoma, Non-small cell lung cancer, Sarcoma, Triple negative breast cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026